Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this trial comes along directing us back to basics. 

estenosis aórtica moderada

In patients with symptomatic aortic stenosis, peaking mortality will clearly justify intervention. But what is the case when there are no symptoms? According to this recent analysis published in JAMA, asymptomatic moderate aortic stenosis does not bring about higher mortality when compared against mild AS

Therefore, we will end up going back to the traditional approach based on symptoms (look closely and wait) when it comes to moderate AS. 

However, the new trend that resorts to prognostic factors to find patients that will benefit from an early intervention must continue

In this study, mortality observed in mild AS was no different from expected mortality in the general population. Patients with moderate AS did show higher mortality risk vs. the general population (though still far from that of severe AS patients). 

This slightly more elevated mortality in moderate AS patients was found in symptomatic patients. Why would moderate AS present with symptoms? The answer to this question is that stenosis might have never been properly assessed and that there might be patients requiring additional markers.


Read also: STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients.


At this point, we might be able to combine the traditional approach with the new trend: waiting for symptoms to show works for most patients; however, some patients (the number still unknown) will benefit from additional assessment and, perhaps, early intervention. 

The VALVENOR included 2703 ambulatory patients with AS. Stenosis degree was defined according to peak velocity in transthoracic ECG, resulting in 42.7% mild AS (2.5 to 2.9 m/sec velocity), 41.5% moderate AS (3 to 3.9 m/sec velocity) and 15.8% severe AS (≥4 m/sec peak velocity).

There were no differences in the rest of baseline characteristics.


Read also: The FDA Approves a Third Device in the TAVR Race.


During followup, 775 patients showed stenosis progress by ECG: 45.2% showed mild to moderate progress, 7.7% mild to severe and 47.1% moderate to severe.

634 of 775 patients who progressed were intervened. Non-intervention was decided upon patient refusal or death while waiting for the procedure. 

Our efforts should aim at finding patients with moderate AS who will progress faster than expected or will die of heart disease (cardiac failure or sudden death). 

Original Title: Association of mortality with aortic stenosis severity in outpatients: results from the VALVENOR study.

Reference: Coisne A et al. JAMA Cardiol. 2021 Sep 29. Online ahead of print. doi: 10.1001/jamacardio.2021.3718. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...